Organogenesis: Market Fixated on ReNu—Wound-Care Cash Flow and a Quiet PuraPly Win Make a Compelling Long
Organogenesis (ORGO) trades at roughly $303M market cap while the market obsesses over ReNu's setbacks. A positive randomized trial for PuraPly AM and steady wound-care cash flow, coupled with elevated short interest and attractive valuation multiples (EV/sales ~0.48; EV/EBITDA ~7.96), create a mid-term trade with defined risk. Entry $2.36, stop $1…